Literature DB >> 10201024

Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration.

R A Cardigan1, H McGloin, I J Mackie, S J Machin, M Singer.   

Abstract

BACKGROUND: Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration (CVVH). Despite adequate exogenous anticoagulation, the occlusion of CVVH circuits can occur within minutes to a few hours of use and is associated with evidence of thrombin generation. Having found no evidence of activation of the contact factor (intrinsic coagulation) pathway during CVVH, we sought to examine the effect of the first episode of CVVH on the tissue factor (extrinsic) pathway of coagulation and thrombin generation.
METHODS: Twelve critically ill patients were studied prior to the commencement of hemofiltration and at regular intervals thereafter until the filter clotted.
RESULTS: Prior to hemofiltration, most patients had increased levels of plasma tissue factor, thrombin-antithrombin (TAT) complexes, and tissue factor pathway inhibitor (TFPI); during hemofiltration, further generation of TAT complexes occurred. Initially, levels of activated factor VII (FVIIa) fell and TFPI increased, but during the course of hemofiltration, the levels of TFPI fell and FVIIa increased. Levels of tissue factor increased during CVVH in some patients, but this was not related to the generation of FVIIa.
CONCLUSIONS: These data indicate that activation of FVII occurred during CVVH, which was related to levels of TFPI, but not tissue factor, and was coincidental to thrombin generation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201024     DOI: 10.1046/j.1523-1755.1999.00397.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

2.  Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit.

Authors:  Sean M Bagshaw; Andrew Davenport
Journal:  Intensive Care Med       Date:  2008-10-08       Impact factor: 17.440

Review 3.  Direct thrombin inhibitors: pharmacology and application in intensive care medicine.

Authors:  Eva Schaden; Sibylle A Kozek-Langenecker
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

4.  Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis.

Authors:  Anne Cornélie J M de Pont; Catherine S C Bouman; Evert de Jonge; Margreeth B Vroom; Harry R Büller; Marcel Levi
Journal:  Intensive Care Med       Date:  2003-05-22       Impact factor: 17.440

5.  The effects of continuous venovenous hemofiltration on coagulation activation.

Authors:  Catherine S C Bouman; Anne-Cornélie J M de Pont; Joost C M Meijers; Kamran Bakhtiari; Dorina Roem; Sacha Zeerleder; Gertjan Wolbink; Johanna C Korevaar; Marcel Levi; Evert de Jonge
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

6.  Hemofiltration induces generation of leukocyte-derived CD31+/CD41- microvesicles in sepsis.

Authors:  Georg Franz Lehner; Ulrich Harler; Clemens Feistritzer; Viktoria Maria Haller; Julia Hasslacher; Romuald Bellmann; Michael Joannidis
Journal:  Ann Intensive Care       Date:  2017-09-04       Impact factor: 6.925

7.  Development and External Validation of a Model for Predicting Sufficient Filter Lifespan in Anticoagulation-Free Continuous Renal Replacement Therapy Patients.

Authors:  Wei Zhang; Ming Bai; Ling Zhang; Yan Yu; Yangping Li; Lijuan Zhao; Yuan Yue; Yajuan Li; Min Zhang; Ping Fu; Shiren Sun; Xiangmei Chen
Journal:  Blood Purif       Date:  2021-10-21       Impact factor: 3.348

Review 8.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.